Skip to main content

Advertisement

SpringerLink
Log in

Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole

  • Pharmacogenetics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

Eradication of H. pylori is an important treatment strategy in peptic ulcer patients. Current regimens of eradication consist of proton pump inhibitor (PPI) and two antibiotics. Effects of PPI may depend on their metabolism, and other factors important for the pathophysiology of peptic ulcer disease. Aim of the present study was to evaluate an association of CYP2C19, MDR1, and IL-1B polymorphisms with the eradication rate of H. pylori in Polish Caucasian patients treated with a triple therapy of pantoprazole, amoxicillin, and metronidazole.

Methods

A total of 139 peptic ulcer patients, positive for H. pylori infection, were treated with triple therapy (pantoprazole + amoxicillin + metronidazole). Subsequently, the patients were divided into two groups (group 1, success, and group 2, failure of eradication after therapy) and genotyped by the PCR-RFLP method for the presence of CYP2C19 variant alleles (*2, *3, and *17), and MDR1 3435C>T and IL-1B +3954C>T polymorphisms. Pantoprazole serum concentrations were measured using the HPLC method.

Results

No significant differences in frequency or distribution of CYP2C19 genotypes were found between the two groups of patients (i.e., with successful H. pylori eradication and treatment failure). However, any carrier of defective CYP2C19*2/*2 genotype was found among patients with treatment failure. Similarly, MDR1 and IL-1B genotypes were found to be significantly associated with the success or failure of H. pylori eradication. Univariate and multivariate analysis of the genotypes did not reveal any significant association between the genotypes and H. pylori eradication. Pantoprazole concentrations differed significantly, and were the highest in patients with defective allele CYP2C19*2 carriers and lowest in hyperactive genotype homozygotes CYP2C19*17/*17.

Conclusion

The results suggest that the CYP2C19 genotype contrary to MDR1 and IL-1B genotypes may have an impact on the efficacy of H. pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC Jr (1989) Effect of varying pH on the susceptibility of Campylobacter Eliopoulos pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 8:888–889

    Article  CAS  PubMed  Google Scholar 

  2. Scott D, Weeks D, Melchers K, Sachs G (1998) The life and death of Helicobacter pylori. Gut 43(Suppl 1):S56–S60

    Article  CAS  PubMed  Google Scholar 

  3. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12:415–416

    Article  CAS  PubMed  Google Scholar 

  4. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T (1997) Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434–442

    CAS  PubMed  Google Scholar 

  5. Barone J, Horn JR (2001) Comparative pharmacology of proton pump inhibitors. Manag Care 10(Suppl 10):11–16

    CAS  PubMed  Google Scholar 

  6. Touw DJ (1997) Clinical implications of genetic polymorphisms and interactions mediated by cytochrome P-450 enzymes. Drug Metabol Drug Interact 14:55–82

    CAS  PubMed  Google Scholar 

  7. Kupfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753–759

    Article  CAS  PubMed  Google Scholar 

  8. Gawronska-Szklarz B, Wrzesniewska J, Starzynska T, Pawlik A, Safranow K, Ferenc K, Drozdzik M (2005) Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 61:375–379

    Article  CAS  PubMed  Google Scholar 

  9. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Ohashi K, Hishida A, Ishizaki T (2007) Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative anitbiotics. Expert Opin Pharmacother 8(16):2701–2717

    Article  CAS  PubMed  Google Scholar 

  10. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69:158–168

    Article  CAS  PubMed  Google Scholar 

  11. Shao JG, Jiang W, Li KQ, Lu JR, Sun YY (2009) Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism. J Dig Dis 10:55–60

    Article  CAS  PubMed  Google Scholar 

  12. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113

    Article  CAS  PubMed  Google Scholar 

  13. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Droździk M (2006) Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 62:877–880

    Article  CAS  PubMed  Google Scholar 

  14. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478

    Article  CAS  PubMed  Google Scholar 

  15. Pauli-Magnus C, Rekersbrink S, Klots U, Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364:551–557

    Article  CAS  PubMed  Google Scholar 

  16. El-Omar EM (2001) The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut 48:743–747

    Article  CAS  PubMed  Google Scholar 

  17. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398–402

    Article  CAS  PubMed  Google Scholar 

  18. Chakravorty M, Ghosh A, Choudhury A, Santra A, Hembrum J, Roychoudhury S (2006) Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer. Hum Mutat 27:411–419

    Article  CAS  PubMed  Google Scholar 

  19. Furuta T, Shirai N, Xiao F, El-Omar EM, Rabkin CS, Sugimura H, Ishizaki T, Ohashi K (2004) Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol 2:22–30

    Article  CAS  PubMed  Google Scholar 

  20. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y (2003) Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol 98:2403–2408

    CAS  PubMed  Google Scholar 

  21. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J (1992) A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 22:396–402

    Article  CAS  PubMed  Google Scholar 

  22. Storms ML, Stewart JT (2002) Stability-indicating HPLC assays for the determination of prilocaine and procaine drug combinations. J Pharm Biomed Anal 30(1):49–58

    Article  CAS  PubMed  Google Scholar 

  23. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P (1991) A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 11:298–302

    CAS  PubMed  Google Scholar 

  24. Goldstein JA, Blaisdell J (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 272:210–218

    Article  CAS  PubMed  Google Scholar 

  25. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174

    Article  CAS  PubMed  Google Scholar 

  26. Hodge PJ, Riggio MP, Kinane DF (2001) Failure to detect an association with IL1 genotypes in European Caucasians with generalised early onset periodontitis. J Clin Periodontol 28(5):430–436

    Article  CAS  PubMed  Google Scholar 

  27. Schabowski J (2001) Is there a territorial differentiation in the prevalence of peptic ulcer among rural population? Ann Agric Environ Med 8:57–62

    CAS  PubMed  Google Scholar 

  28. Narikawa S (1986) Distribution of metronidazole susceptibility factors in obligate anaerobes. J Antimicrob Chemother 18:565–574

    Article  CAS  PubMed  Google Scholar 

  29. Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S, Ikuma M, Yamada S, Watanabe H, Hishida A, Furuta T (2009) Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol 65(6):593–600

    Article  CAS  PubMed  Google Scholar 

  30. Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Umemura K, Ishizaki T, Hishida A (2007) Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP2C19 genotypes and 23 S rRNA genotypes of H. pylori. Aliment Pharmacol Ther 26:693–703

    CAS  PubMed  Google Scholar 

  31. Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, Goral V, Kupcinskas L, Kantarceken B, Aydin A, Archimandritis A, Dzierzanowska D, Vcev A, Ivanova K, Marina M, Mitov I, Petrov P, Ozden A, Popova M (2002) The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 8:388–396

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors highly appreciate the statistical assistance of Dr. Krzysztof Safranow.

Author information

Authors and Affiliations

  1. Department of Pharmacology, Pomeranian Medical University, Powstancow Wlkp. 72, 70-111, Szczecin, Poland

    Barbara Gawrońska-Szklarz, Mateusz Kurzawski & Marek Droździk

  2. Clinical Department of Internal Diseases, Regional Hospital, Piłsudskiego 8, 66-530, Drezdenko, Poland

    Andrzej Siuda

  3. Department of Gastroenterology, Pomeranian Medical University, Powstancow Wlkp. 72, 70-111, Szczecin, Poland

    Dariusz Bielicki & Wojciech Marlicz

Authors
  1. Barbara Gawrońska-Szklarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrzej Siuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mateusz Kurzawski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dariusz Bielicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wojciech Marlicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marek Droździk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marek Droździk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gawrońska-Szklarz, B., Siuda, A., Kurzawski, M. et al. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol 66, 681–687 (2010). https://doi.org/10.1007/s00228-010-0818-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-010-0818-1

Keywords

Search

Navigation